Introduction {#s1}
============

Uveitis included a group of heterogeneous diseases characterized by inflammation of the uveal tract. It is an important cause of vision loss accounting for approximately 25% of total blindness in developed countries, particularly among the working-age population ([@B85]). Uveitis may be generally classified by the etiology of inflammation as infectious or non-infectious (autoimmune disorders), which could be related or not to a systemic disease. If after a comprehensive investigation there is no a clear cause of inflammation, it is considered as idiopathic ([@B56]). The differential diagnosis for autoimmune uveitis includes systemic inflammatory diseases---such as spondyloarthropathies (SPA), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), Behçet\'s disease (BD), sarcoidosis, or juvenile idiopathic arthritis (JIA)-, and autoimmune diseases that preferentially affect ocular tissues---such as Vogt-Koyanagi-Harada (VKH), white dot syndromes, sympathetic ophthalmia, and birdshot chorioretinopathy (BCR). In addition, uveitis can be anatomically classified as anterior, intermediate, posterior or panuveitis, and they may have an acute, chronic or recurrent course. The clinical presentation is variable, the symptoms may include blurred vision, photophobia, ocular pain and significant visual impairment ([@B34]). The etiology of uveitis depends on environmental, cultural, and genetic factors ([@B10]). In a recently published work by our group, uveitis was found to be secondary to a non-infectious autoimmune disease in 42% of cases. Infectious agents cause another 16.8%, while the condition remains idiopathic in the remaining 41% ([@B43]).

Pathophysiology of Uveitis {#s1_1}
--------------------------

The pathophysiology understanding of intraocular inflammation is limited. The eye has immunological properties known as "immune privilege," in which conventional immune response in not evoked by foreign antigens placed in those tissues. The haemato-ocular barriers, the lack of cell expression of both MHC-I and MHC-II, and the presence of immune modulators, such as TGF-β, among others, give this feature to the eye ([@B43]).

It is thought that most non-infectious uveitis (NIU) are mediated by T cells, predominantly CD4+ T cells that exhibit a Th1 phenotype. Although the exact pathogenesis of uveitis is not completely understood, cytokines such as IL-2, TNF-α, INF-γ, IL-12, and IL-17 have been detected in patients with active disease, and it is believed that they would be key players in the pathogenesis ([@B16]; [@B42]; [@B15]). Thus, these cytokines may be therapeutic targets for new treatments of NIU, whose management represents a challenge, given the broad variability in its nature and pathophysiology.

Treatment of Non-Infectious Uveitis {#s1_2}
-----------------------------------

The first line of treatment for NIU corresponds to corticosteroids (CS), particularly due to their high efficacy and rapid control of acute inflammation. Depending on the severity of the condition and the type of ocular involvement, CS can be administered topically, periocularly, intraocularly, or systemically ([@B60]; [@B35]; [@B62]). However, systemic CS have been associated not only with a significant number of systemic adverse effects with long-term therapy---including diabetes, Cushing\'s syndrome, hypercholesterolemia, and osteoporosis---but also cataracts and glaucoma, which can ultimately result in visual impairment and blindness ([@B63]; [@B60]; [@B54]). The most studied and used CS is prednisolone, having the greatest clinical evidence supporting its use ([@B32]; [@B3]; [@B29]; [@B74]). In some clinical scenarios, immunosuppressant therapy (IMT)---such as antimetabolites (methotrexate, mycophenolate mofetil, azathioprine), calcineurinic inhibitors (cyclosporine, tacrolimus), and alkylating agents (cyclophosphamide, chlorambucil)---is required to treat uncontrolled inflammation ([@B35]; [@B28]; [@B62]). In addition, these drugs are the standard of care in some clinical entities, such as BD, BCR, or pediatric uveitis, due to the higher prevalence of chronic disease (e.g., JIA-associated uveitis) in this last subset of patients ([@B35]; [@B81]; [@B8]).

Biological therapy has emerged as a new therapeutic approach in pediatric and adulthood uveitis, based on targeting relevant immunological pathways involved in disease pathogenesis, particularly tumor necrosis factor alpha (TNF-α) ([@B35]; [@B81]; [@B8]; [@B28]).

Anti TNF-α Drugs {#s1_3}
----------------

TNF-α is a pro-inflammatory cytokine that participates in the pathophysiology of autoimmune and inflammatory diseases, and thus, it has become an important therapeutic target ([@B37]). TNF-α blockers have been used for the treatment of rheumatic diseases since 1999 and have dramatically changed the clinical course of invalidating diseases, such as RA and SPAs ([@B48]). Noteworthy, several trials and case series have already demonstrated the effectiveness of anti-TNF-α for treating refractory uveitis ([**Table 1**](#T1){ref-type="table"}) ([@B36]; [@B90]), showing a reduction of inflammatory signs and relapses, as well as an increase of the likelihood of visual acuity preservation (more than 90% in some cases) and the quality of life of uveitis patients ([@B20]; [@B40]; [@B72]). If uveitis is refractory to systemic CS and IMT or patients become intolerant to such therapies, a good sight-saving measure is the use of biological agents ([@B51]; [@B88]).

###### 

Current anti-TNF-α available treatments in non-infectious uveitis.

  Therapy               Description                                                     Study type          References
  --------------------- --------------------------------------------------------------- ------------------- ------------
  Adalimumab            Anti TNF-α humanized antibody                                   Clinical trial      ([@B13])
                                                                                        Systematic review   ([@B5])
  Clinical trial        ([@B33])                                                                            
  Clinical trial        ([@B25])                                                                            
  Prospective study     ([@B72])                                                                            
  Meta-analysis         ([@B40])                                                                            
  Systematic review     ([@B39])                                                                            
  Clinical trial        ([@B83])                                                                            
  Clinical trial        ([@B41])                                                                            
  Retrospective study   ([@B51])                                                                            
  Clinical trial        ([@B55])                                                                            
  Infliximab            Anti TNF-α chimeric antibody                                    Systematic review   ([@B5])
  Prospective study     ([@B72])                                                                            
  Meta-analysis         ([@B40])                                                                            
  Systematic review     ([@B39])                                                                            
  Retrospective study   ([@B51])                                                                            
  Golimumab             Anti TNF-α humanized antibody                                   Systematic review   ([@B5])
  Meta-analysis         ([@B40])                                                                            
  Systematic review     ([@B39])                                                                            
  Etanercept            Anti TNF-α dimeric protein, act as a decoy for TNF-α Receptor   Meta-analysis       ([@B40])
  Systematic review     ([@B39])                                                                            
  Certolizumab          Anti TNF-α antibody                                             Systematic review   ([@B40])
  Systematic review     ([@B39])                                                                            

TNF-α, tumor necrosis factor alpha.

### Adalimumab {#s1_3_1}

Adalimumab (Humira^®^) is an entirely humanized monoclonal antibody against TNF-α which is may be subcutaneously self-administered. It is the most used and studied biologic medication for the treatment of adulthood NIU since its approval in 2016 ([@B5]; [@B31]).

The first report of adalimumab\'s role in the treatment of NIU was in 2008 ([@B13]). Subsequently, large multicenter randomized clinical trials (Visual I, II, and III) have showed this drug is effective in non-anterior NIU for inflammation control and as steroid-sparing agent ([@B13]; [@B33]; [@B55]; [@B39]; [@B41]; [@B83]; [@B25]). The Visual I study was a multinational phase 3 trial where adalimumab given fortnightly, was used to treat active non-infectious intermediate, posterior, and panuveitis. The authors showed the rate of treatment failure was slashed to 50% in the adalimumab group compared with placebo ([@B33]). In the Visual II multicenter, randomized trial, adalimumab also lowered the risk of uveitis recurrence or vision loss, upon steroids withdrawal, in patients with inactive, non-infectious intermediate, posterior, and panuveitis, controlled by moderate systemic steroids dose. Treatment failure occurred in 55% of patients in the placebo group compared with 39% of patients in the adalimumab group ([@B55]). Noteworthy, although the good efficacy shown in these trials, further studies have found up to 40% of therapeutic failure after 12 months of treatment ([@B83]).

In pediatric patients, adalimumab was approved in 2017 ([@B31]; [@B70]; [@B83]). The combination of adalimumab with CS has been described as beneficial in terms of lowering therapeutic failure rate ([@B79]). Ramanan et al. published a randomized trial that compared efficacy of adalimumab in children with active JIA-related uveitis despite methotrexate. In their work, patients assigned to the adalimumab arm had a significant lower treatment failure compared with placebo (27% vs 60%; *p* \< 0.0001) ([@B61]). However, drug-induced remission of JIA-associated uveitis did not persist when the drug was withdrawn after 1 to 2 years of treatment ([@B30]). In addition, it has been showed that adalimumab is more effective for controlling inflammation and lowering relapses in pediatric NIU, in comparison with infliximab and etanercept ([@B76]; [@B79]).

Pediatric doses are started with a minimum of 24 mg/m^2^, and a maximum of 40 mg weekly. Adult scheme doses are started with a loading dose of 80 mg, and then maintenance of 40 mg every 2 weeks ([@B79]; [@B81]).

Importantly, a bimodal agent of adalimumab (SB5) has been recently approved for the treatment of NIU and other autoimmune entities, such as RA, JIA, IBD, among others ([@B23]).

### Infliximab {#s1_3_2}

Infliximab (Remicade^®^) is a chimeric monoclonal antibody used since 2001 ([@B69]). It has 25% murine and 75% humanized domains. Its use is FDA-approved for RA, psoriatic arthritis (PsA), IBD, and AS, but not for NIU. It is only intravenously administered, usually in conjunction with methotrexate to prevent the generation of antibodies against the drug ([@B48]; [@B81]).

There is great evidence of its efficacy in NIU, mainly BD ([@B69]; [@B90]; [@B19]). Maleki et al., in a small retrospective case series, achieved remission in 19 of 23 patients with active intermediate NIU refractory to at least one IMT ([@B49]). Along the same line, Baughman et al. showed a remarkable improvement in 13 out of 14 patients with several underlying causes of ocular inflammation, who were treated with infliximab after failure of classical IMT ([@B2]) In other retrospective study, Bodaghi et al. achieved a rapid control of uveitis in all 12 patients refractory to CS and IMT ([@B4]). Suhler et al. conducted a prospective non-comparative trial of infliximab therapy for refractory uveitis, in which 18 out of 23 patients met criteria for clinical success at week 10 ([@B82]).

Nevertheless, despite these good results, some studies have indicated that the rate of therapeutic failure at 12 months of treatment is around 60% ([@B4]; [@B76]; [@B77]), which puts it at a disadvantage compared to adalimumab. However, infliximab presents a rapid onset of action, which is why it is recommended in severe exacerbations ([@B69]; [@B50]).

The posology is very variable. In adults, the dose and frequency depend on the disease, which can be between 3 and 5 mg/kg every 6 to 8 weeks. The pediatric dose begins with a loading dose between 3 and 5 mg/kg at weeks 0, 2, and 6, and continues with a maintenance dose of at least 7.5 mg/kg/dose every 4 to 8 weeks; the dose is adjusted according to the clinical response and the patient\'s tolerance to the medication, with a evaluated maximum dose of 20 mg/kg ([@B84]; [@B81]).

### Golimumab {#s1_3_3}

Golimumab (Simponi^®^) is a fully humanized monoclonal antibody, subcutaneously administered with a dose of 50 mg every 4 weeks. Its use has been approved for the treatment of AS, RA, PsA, and UC ([@B84]; [@B7]). There is little evidence, but it has been described its efficacy in patients with NIU refractory to adalimumab or infliximab, and thus golimumab is usually reserved as treatment for this subset of non-responders ([@B52]; [@B7]; [@B21]). In that sense, this medication would present a higher affinity for the receptor, being able to improve clinical signs of inflammation in refractory patients ([@B86]). Tosi et al. published a retrospective study of 21 uveitis patients treated with Golimumab (10 patients) or Certolizumab pegol (11 patients). They showed a significant reduction in ocular flares from 128.6 events/100 patients-year to 24.9 events/100 patients-years, although no specific results were published for each group. All patients in the Golimumab group had received another anti-TNF drug previously ([@B86]). Additionally, Palmou-Fontana et al. showed complete remission of four of seven patients with JIA-associated uveitis treated with golimumab ([@B57]).

### Etanercept {#s1_3_4}

The mechanism of action of etanercept (Enbrel^®^) differs from the other anti-TNF-α agents. It is a dimeric protein that has an Fc portion of human IgG and a portion of the ligand-binding site of the TNF receptor p75 ([@B66]). Etanercept is subcutaneously administrated at a dose of 50 mg once per week or 25 mg twice a week. In children over 2 years old, etanercept is approved for the treatment of JIA at the dose of 0.4 mg/kg (up to a maximum of 25 mg/dose) twice a week or 0.8 mg/kg (maximum 50 mg) once weekly ([@B27]).

There is little evidence about this medication, and case reports indicate that although patients with BD respond to therapy, this effect is not sustained ([@B79]). Etanercept is no longer prescribed for uveitis given its low distribution in ocular tissue, and its lower efficacy compared to adalimumab and infliximab ([@B22]; [@B89]; [@B87]).

### Certolizumab {#s1_3_5}

Certolizumab (Cimzia^®^) is a recombinant humanized monoclonal antibody administered subcutaneously at an initial dose of 400 mg at weeks 0, 2, and 4 and then 200 mg per week. It is approved for the treatment of AS, PsA, RA, and Crohn\'s disease ([@B44]). It has been little studied in NIU, and in general, it has been evaluated in small case series. However, it has shown positive results, and no major adverse effects have been reported during its use ([@B64]; [@B45]). It seems to have a better and higher distribution toward inflamed tissues than adalimumab and infliximab ([@B44]). A recent study has indicated that both golimumab and certolizumab represent effective and safe options for patients with uveitis even if the result with other anti-TNF-α drugs has not been successful ([@B86]).

Adverse Effects of Anti TNF-α Drugs {#s1_4}
-----------------------------------

As adalimumab and golimumab are fully humanized antibodies, they have less immunogenic potential than chimeric antibodies ([@B79]). The main adverse effects of anti-TNF-α agents include development of autoimmune diseases, increased risk of infection, where tuberculosis and histoplasmosis stand out, among others. Reactions at the injection site have been also described. In addition, anti-TNF-α blockers have been associated with an increased risk of malignancy, mainly lymphomas ([@B12]), although further studies have ruled this out ([@B73]) and with debut or worsening of demyelinating disorders, such as multiple sclerosis ([@B47]).

Adverse effects of adalimumab also include arthralgias, nasopharyngitis, and headaches. Side effects of infliximab may include the development of mild or severe lupus-like symptoms (9% and 1% respectively) ([@B42]). Golimumab may cause nausea, fever, and anemia ([@B12]). In the case of etanercept, uveitis, IBD flares, and granulomatous diseases have been shown to be more prevalent compared to other TNF blockers ([@B66]; [@B27]). Certolizumab has been little studied in NIU, and in general, it has been evaluated in small case series, showing positive results and mild or moderate adverse effects during its use ([@B64]; [@B46]), with infections being the most common ([@B6]), and in fewer cases it has been reported a generalized skin reaction (in the third administration), anaphylactic reactions, and a lupus-like episodes ([@B6]).

A significant proportion of patients experiences loss of response during maintenance treatment with anti-TNF-α, due to the development of an immune response directed at the drug itself, leading to lower concentration of anti-TNF-α and the presence of anti-anti TNF-α antibodies in serum ([@B26]; [@B87]). The measurement of drug concentrations and probably, the measurement of anti-infliximab or anti-adalimumab antibodies, might be useful for improving the selection of patients who would benefit from the maintenance treatment with infliximab or adalimumab, avoiding inappropriate treatments, and helping to decide which procedure to follow in case of loss of response ([@B26]). However, there is no enough evidence to recommend level or antibody measurements as standard of care in uveitis patients.

IMT are added in order to reduce the immunogenicity against anti-TNF-α drugs. Although there is no solid evidence-based data regarding their use, the use of an immunosuppressant together, such as methotrexate, is suggested in case of pathologies-associated uveitis (e.g. BD, JIA, etc.) ([@B87]).

Other Biologics Therapies {#s1_5}
-------------------------

When conventional IMT and/or anti-TNF-α therapies fail, other biological agents are recommended. Some of the newest therapies have focused on blocking interleukin actions ([**Table 2**](#T2){ref-type="table"}).

###### 

Current available non--anti-TNF Biologics treatments in non-infectious uveitis.

  Therapy               Description                       Study type          References
  --------------------- --------------------------------- ------------------- ------------
  Tocilizumab           Anti-IL-6 humanized antibody      Systematic review   ([@B45])
  Clinical trial        ([@B58])                                              
  Systematic review     ([@B8])                                               
  Systematic review     ([@B71])                                              
  Retrospective study   ([@B75])                                              
  Secukinumab           Anti-IL-17A monoclonal antibody   Clinical trial      ([@B14])
  Review                ([@B65])                                              
  Canakinumab           Anti-IL-1β                        Case report         ([@B78])
  Systematic review     ([@B80])                                              
  Anakinra              IL-1 receptor antagonist          Systematic review   ([@B80])
  Rituximab             Anti CD20 antibody                Systematic review   ([@B80])
  Retrospective study   ([@B53])                                              
  Clinical trial        ([@B11])                                              

IL, interleukin; CD, cluster of differentiation.

Anti-IL-6 Therapies {#s1_6}
-------------------

Interleukin-6 (IL-6) is a proinflammatory cytokine implicated in various immune-mediated diseases. Its produced by monocytes, macrophages, B cells, and T cells mainly. In some pathologies, such as central retinal vein occlusion, diabetes, or uveitis, intraocular concentrations of IL-6 are increased ([@B59]). The recombinant human monoclonal antibody tocilizumab (Actemra^®^) is an IL-6 receptor blocker and has shown a good effect in the treatment of NIU ([@B45]), particularly in BD patients with refractory uveitis ([@B1]). FDA approved the use of tocilizumab for the management of RA, including refractory patients ([@B28]). In general, tocilizumab, presents minor adverse effects such as chest tightness, fatigue, nausea, and blisters on the hands and limbs ([@B75]; [@B71]), non-serious bronchitis, leukopenia, and thrombocytopenia in which the drug was not suspended ([@B58]). However, cases with more severe manifestations such as neutropenia, unacceptable dizziness and nausea, severe infusion reaction, severe angioedema, and severe abdominal pain have been reported, requiring discontinuation of the medication ([@B75]; [@B1]). There is a reported case of probable association of anxiety, sweating, and flushing with the infusion ([@B68]).

### Anti-IL-1 Therapies {#s1_6_1}

Anti-IL-1 treatment includes antagonist of the IL-1 receptor, anakinra (Kineret^®^), and anti-IL-1β antibody, canakinumab (Ilaris^®^). Both anti-IL-1s were evaluated in a multicenter retrospective study that included 19 BD-associated uveitis patients. In this study, both treatments were effective in the management of uveitis, providing a good control of inflammation and steroid-sparing effect, in refractory and long-lasting cases ([@B18]). IL-1 blockers have shown mild adverse effects, confirming their excellent safety profile ([@B18]). In the case of anakinra the most reported manifestations are headaches and arthralgias ([@B38]; [@B9]). There is only a reported case of reactivation of pulmonary TB, but in an elderly patient with RA and record of pulmonary TB ([@B9]).

### Anti-CD20 Therapies {#s1_6_2}

Rituximab (Rituxan^®^/MabThera^®^) is a chimeric (human and murine portion) monoclonal antibody directed against the CD20 antigen present on the B-cells surface. In 1997 it was approved to treat lymphoma, and its use has continued to control other diseases, such as RA ([@B11]). In a retrospective study with JIA-related uveitis patients, all achieved complete control of uveitis within 5 months of first infusion over a mean follow up of 44 months, demonstrating the long-term efficacy of rituximab for anti-TNF-α refractory cases ([@B53]). In addition, rituximab was effective for treating resistant ANCA-positive vasculitis, with no significant adverse effects ([@B17]). Regarding adverse effects, there are minor cases of hives and flushing, and others more severe that have required the suspension of the infusion. Infection-like pneumonia and herpes zoster have been also reported ([@B11]).

### Anti-CD25 Therapies {#s1_6_3}

Daclizumab is a monoclonal antibody targeted to 2α subunit of the IL-2 receptor on activated T-cells, blocking the conventional T-cells immune responses ([@B67]; [@B24]). In this case, mild adverse effects are more frequent than serious. The most frequently reported adverse effects have been on the one hand herpes zoster, rash, and palpitations, and the other liver disorders and elevated transaminases, although mainly asymptomatic and self-limited ([@B67]; [@B24]).

### Anti-IL-17A Therapies {#s1_6_4}

Secukinumab is a monoclonal antibody (fully humanized) that binds and neutralizes the IL-17A ([@B14]; [@B65]). Some problems in the upper respiratory tract (nasopharyngitis) and headache has been reported as adverse effects, and it has been seen cases of reactivation of uveitis, as well as arthralgias ([@B14]).

Conclusions {#s2}
===========

Biologic agents have revolutionized the immunological treatment of NIU in the past 20 years. The most newly published guidelines for uveitis management suggest a step-ladder approach, starting with topical, periocular, and systemic CS, followed by IMT, and finally the use of biologic therapy (preferably a TNF-α inhibitor). In this sense, despite the well-known side effects of CS, they remain as the cornerstone of treatment for acute diseases and exacerbations. Furthermore, the use of new therapies is still limited due to their high cost, and all the aspects that remain to be studied, such as follow-up regimens and monitoring. Nevertheless, it would not be a surprise that, with the availability of new data, biological agents may be recommended as first-line therapy in the management of some causes of uveitis. Furthermore, new insights have emerged to present new therapeutic approaches directed against immune components as potential novel therapies for NIU.
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